These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12111108)

  • 1. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
    Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
    Ando Y; Kawada K; Inada M; Morita S; Mitsuma A; Yasuda Y; Hiramatsu M; Fujimoto Y; Fujita K
    Oncology; 2012; 83(1):38-44. PubMed ID: 22722580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
    Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
    Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.